読み込み中
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
前日終値
$7.055
+$0.235 · +3.45%
日中の時刻はETです。市場データは遅延する場合があります。
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
日中レンジ
現在 $7.055
52週レンジ
現在 $7.055
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
37
割高
センチメント
60
まちまち
リスク
56
やや高いリスク
モメンタム
56
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
日中レンジ
現在 $7.055
52週レンジ
現在 $7.055
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 279.7万 USD | 3891.3万 USD | 2600.4万 USD | 1.11億 USD | 8507.7万 USD |
| 売上原価 | — | — | — | 203.7万 USD | — |
| 粗利益 | 279.7万 USD | 3891.3万 USD | 2600.4万 USD | 1.09億 USD | 8507.7万 USD |
| 研究開発 | 5803.4万 USD | 4510.5万 USD | 7126万 USD | 7237.7万 USD | 6873.6万 USD |
| 販売・一般管理 | 3146.8万 USD | 3012.6万 USD | 4045万 USD | 2386.2万 USD | 2093.8万 USD |
| 営業費用 | 8950.2万 USD | 8281万 USD | 1.12億 USD | 9420.2万 USD | 8967.4万 USD |
| 受取利息 | 657.9万 USD | 738.6万 USD | 496.4万 USD | — | — |
| 支払利息 | — | — | 283.3万 USD | 303.1万 USD | 284.4万 USD |
| 減価償却費と償却費 | 295.9万 USD | 115.1万 USD | 84.3万 USD | 128.7万 USD | 125.2万 USD |
| 営業利益 | −8670.5万 USD | −4389.7万 USD | −8641.6万 USD | 1453.8万 USD | −459.7万 USD |
| 純利益 | −1.3億 USD | −7742.4万 USD | −2.2億 USD | 3537.9万 USD | −2568.7万 USD |
会社概要が更新されました 2026年10月10日.
| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2024年4月5日 | 1:30 | — | — |
発効済み 2024年4月5日
1:30
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
